Letter Concerning Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence. Copeland TP. Ann Neurol 2026 Apr 7. doi: 10.1002/ana.78218.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Copeland TP. Letter Concerning Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence. Ann Neurol 2026 Apr 7. doi: 10.1002/ana.78218.
PMID: 41947396